indication directory

Asthma clinical trial intelligence

Trials are included only when the source condition or controlled indication mapping directly matches this disease area. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

indication

Association rule

source condition

NCT01520688

Source recordAI-normalized

A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma

A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma is a PHASE4 clinical asset sponsored by West Penn Allegheny Health System in Asthma. SEO and diligence focus: Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI analysis

Indication: Asthma

Modality: small molecule

Target: Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone

Sponsor: West Penn Allegheny Health System

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Asthma

View original source fields

Condition raw: Asthma

Condition normalized: Asthma

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone

Target normalized: Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone

Open report

NCT03011632

Source recordAI-normalized

The Role of Nonspecific Immune Response of the Airway Mucosa in Children With Chronic Rhinosinusitis and Asthma

The clinical trial, sponsored by the Medical University of Lodz, investigates the efficacy of intranasal glucocorticosteroids (mometasone) in children with chronic rhinosinusitis and asthma. Given the increasing prevalence of asthma and CRS in pediatric populations, successful outcomes could position mometasone as a preferred treatment option, enhancing market share in the pediatric respiratory therapeutics segment. The trial's completion in August 2019 allows for timely analysis of results, which may inform future product development and marketing strategies. Additionally, the focus on specific immunoglobulin responses and innate immune mechanisms may open avenues for novel therapeutic targets and partnerships in immunology and respiratory medicine.

AI analysis

Indication: Sinusitis

Modality: small molecule

Target: Nonspecific immune response of the airway mucosa, specifically focusing on the role of innate lymphoid cells (ILCs) and their interaction with epithelial cells in chronic rhinosinusitis (CRS) and asthma.

Sponsor: Medical University of Lodz

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 21, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Asthma

NCT01881412

Source recordAI-normalized

Optimizing Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

The study aimed to evaluate the effectiveness of prescribing inhaled corticosteroids (ICS) in the emergency department for children with uncontrolled asthma. Given the high prevalence of asthma in children and the significant healthcare costs associated with emergency visits, successful implementation of this intervention could lead to improved patient outcomes and reduced healthcare utilization. However, the trial was terminated due to funding completion, which may limit further exploration of this approach. The market for asthma medications, particularly ICS, remains competitive, with established players dominating. The findings could influence future strategies for asthma management in pediatric populations, but the termination of this trial may hinder immediate commercial opportunities.

AI analysis

Indication: Asthma

Modality: small molecule

Target: Inhaled corticosteroids (ICS) - specifically fluticasone, targeting inflammation in the airways to improve asthma control.

Sponsor: Rhode Island Hospital

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 10, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Asthma

NCT04641741

Source recordAI-normalized

Effect of Mepolizumab on the Phenotype/Proteome/Transcriptome of Eosinophils in Severe Eosinophilic Asthma

Mepolizumab, an IL-5 antagonist, is being evaluated for its efficacy in severe eosinophilic asthma, a market segment with significant unmet needs. The study aims to identify predictive and prognostic biomarkers for treatment response, which could enhance patient stratification and improve therapeutic outcomes. Given the increasing prevalence of asthma and the growing demand for targeted biologics, successful outcomes could position mepolizumab favorably against competitors like dupilumab and other emerging therapies. The collaboration with GlaxoSmithKline indicates strong industry backing, potentially facilitating broader market access and commercialization strategies.

AI analysis

Indication: Asthma

Modality: small molecule

Target: IL-5 receptor (CD125) on eosinophils

Sponsor: Hospital Clinico Universitario de Santiago

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 10, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Asthma

View original source fields